首页> 外国专利> Treatment and prevention of hypersensitivity and / or anaphylaxis with anti-IgE antibodies in patients undergoing replacement therapy

Treatment and prevention of hypersensitivity and / or anaphylaxis with anti-IgE antibodies in patients undergoing replacement therapy

机译:抗IgE抗体对正在接受替代治疗的患者的过敏反应和/或过敏反应的治疗和预防

摘要

The present invention relates generally to a method of treatment and/or prevention of hypersensitivity including anaphylaxis in patients receiving replacement therapy molecules that elicit an IgE-mediated response by administering an anti-IgE antibody or a binding fragment thereof. Anti-IgE antibodies inhibit IgE-mediated allergic reactions in the mammals and can also lower the risk of an anaphylactic reaction to a replacement therapy molecule. The administration of anti-IgE antibodies over time also downregulates the high-affinity IgE receptor, further decreasing the risk of hypersensitivity and/or anaphylaxis. The anti-IgE antibody binds to circulating or serum IgE and/or membrane form IgE on B-cells, but not to IgE bound to mast cells or basophils, as this may cause crosslinking. This method also reduces the dose and/or frequency of administration of the replacement therapy molecule by reducing or eliminating neutralizing IgE antibodies specific for the replacement therapy molecule.
机译:本发明总体上涉及治疗和/或预防超敏反应的方法,包括对接受替代治疗分子的患者进行过敏反应,所述替代治疗分子通过施用抗IgE抗体或其结合片段引发IgE介导的应答。抗IgE抗体抑制哺乳动物中IgE介导的过敏反应,还可以降低对替代治疗分子发生过敏反应的风险。随着时间的推移,抗IgE抗体的给药也下调了高亲和力的IgE受体,从而进一步降低了过敏和/或过敏反应的风险。抗IgE抗体与B细胞上的循环或血清IgE和/或膜形式IgE结合,但不结合与肥大细胞或嗜碱性粒细胞结合的IgE,因为这可能引起交联。该方法还通过减少或消除对替代治疗分子特异的中和IgE抗体来减少替代治疗分子的剂量和/或施用频率。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号